D-BSSE spinoff deepCDR Biologics AG wins Venture Kick

Currently, drug-developers searching for new therapeutic antibodies use time-consuming, experimental screening processes that can take years to develop candidates ready for clinical trial. DeepCDR co-founders Derek Mason and Simon Friedensohn from the Sai Reddy group combine gene editing, deep sequencing and deep learning to radically accelerate the therapeutic antibody discovery process. Winning Venture Kick offers the startup access to the next level of entrepreneurial training.